The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 54, Issue 5, 2005, Pages 677-681

  Saklamaz, Ali ^a   Comlekci, Abdurrahman ^a   Temiz, Aysegul ^a   Caliskan, Sezer ^a   Ceylan, Cengiz ^a   Alacacioglu, Ahmet ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 17844364863     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.12.012     Document Type: Article

References (42)

1. W.P. Castelli, R.J. Garrison, and P.W.F. Wilson Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study JAMA 256 1986 2835 2838
2. R. Koppensteiner, E. Minar, and H. Ehringer Effect of lovastatin on hemorheology in type II hyperlipoproteinemia Atherosclerosis 83 1990 53 58
3. W. Koenig, M. Sund, and B. Filipiak Plasma viscosity and the risk of coronary heart disease. Results from the MONICA-Augsburg Cohort Study, 1984 to 1992 Arterioscler. Thromb. Vasc. Biol. 18 1998 768 772
4. G.D.O. Lowe, B. McArdle, and P. Stromberg Increased blood viscosity and fibrinolytic activity in type II hyperlipoproteinemia Lancet 1 1982 472 475
5. A. Vaya, M. Martinez, and J. Dalmau Hemorheological profile in patients with cardiovascular risk factors Haemostasis 26 Suppl. 4 1996 166 170
6. P.M. Sweetnam, H.E. Thomas, and J.W.G. Yarnell Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease Eur. Heart J. 17 1996 1814 1820
7. R.S. Rosenson, and G.D.O. Lowe Effects of lipids and lipoproteins on thrombosis and rheology Atherosclerosis 140 1998 271 280
8. G. Mchdlishvili, and N. Maeda Blood flow structure related to red cell flow: A determinant of blood fluidity in narrow microvessels Jpn. J. Physiol. 51 2001 19 30
9. R.H. Jay, M.W. Rampling, and D.J. Betteridge Abnormalities of blood rheology in familial hypercholesterolemia: Effects of treatment Atherosclerosis 85 1990 249 256
10. M. Martinez, A. Vaya, and R. Marti Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia Haemostasis 26 Suppl. 4 1996 171 176
11. M. Kohno, K. Murakawa, and Y. Kenichi Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients Metabolism 46 3 1997 287 291
12. P. Miossec, F. Zkhiri, and J. Paries Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled type 2 diabetic patients Diabet. Med. 16 1999 424 430
13. C.A. Dujovne, W.S. Harris, and R. Altman Effect of Atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients Am. J. Cardiol. 85 2000 350 353
14. R.S. Rosenson, and C.C. Tangney Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction JAMA 279 1998 1643 1650
15. R. Krysiak, B. Okopien, and Z.S. Herman Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes Drugs 63 17 2003 1821 1854
16. E.M. Balk, J. Lau, and C. Goudas Effects of statins on nonlipid serum markers associated with cardiovascular disease Ann. Intern. Med. 139 8 2003 670 682
17. Y. Beigel, J. Fuchs, and M. Snir Lovastatin therapy in heterozygous familial hypercholesterolemic patients: Effect on blood rheology and fibrinogen levels J. Intern. Med. 230 1991 23 27
18. A.S. Wierzbicki, P.J. Lumb, and Y.K. Semra Effect of atorvastatin on plasma fibrinogen Lancet 351 1998 569 570
19. B. Staels, J. Dallongeville, and J. Auwerx Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
20. A. Clauss Rapid physiological coagulation method for the determination of fibrinogen [German] Acta Hematol 17 1957 237 246
21. R.S. Schwartz, J.W. Madsen, and A.C. Rybicki Oxidation of spectrin and deformability defects in diabetic erythrocytes Diabetes 40 1991 701 708
22. S.B. Solerte, C. Viola, and G.P. Carnavale-Schianca Acute phase protein reactant pattern and alpha 2 macroglobulin in diabetes pathophysiological aspects in diabetic microangiopathy Ric. Clin. Lab. 14 1984 574 578
23. S.B. Solerte, S. Adamo, and C. Viola Blood rheology changes and proteinuria in complicated diabetes mellitus Giorn. Hal. Diabetol. 4 1984 245 249
24. M.L. Larsen, and D.R. Illingworth Drug treatment of dyslipoproteinemia Med. Clin. North Am. 78 1994 225 229
25. A.P. Lea, and D. McTavish Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias Drugs 53 1997 828 831
26. H. Lennernas, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences Clin. Pharmacokinet. 32 1997 403 425
27. J.A. Balfour, D. McTavish, and R.C. Heel Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia Drugs 40 1990 260 290
28. J.C. Fruchart, H.B. Brewer, and E. Leitersdorf Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease Am. J. Cardiol. 81 1998 912 919
29. E.T. Bairaktari, C.S. Tzallas, and V.K. Tsimihodimos Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia J. Cardiovasc. Risk 6 2 1999 113 116
30. M. Kockx, P.P. Gervois, and B. Derudas Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha Blood 93 9 1999 2991 2998
31. R.J.A. Frost, C. Otto, and C. Geiss Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia Am. J. Cardiol. 87 2001 44 48
32. P. Lijnen, R. Fagard, and J. Staessen Erythrocyte membrane lipids and cationic transport systems in men J. Hypertens. 10 1992 1205 1211
33. P. Kanakaraj, and M. Singh Influence of hypercholesterolemia on morphological and rheological characteristics of erythrocytes Atherosclerosis 76 1989 209 218
34. C. Otto, M.M. Ritter, and A.C. Soennichsen Effects of n-3 fatty acids and fenofibrate on lipid and hemorheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia Metabolism 45 10 1996 1305 1311
35. M. Labios, M. Martinez, and A. Vaya Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients Clin. Hemorheol. Microcirc. 21 1999 79 85
36. W. Koenig, and E. Ernest The possible role of hemorheology in atherothrombogenesis Atherosclerosis 94 1992 93 107
37. Y. Levy, R. Leibowitz, and M. Aviram Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolemia Br. J. Clin. Pharmacol. 34 5 1992 427 430
38. R.A. Cooper, E.C. Arner, and J.S. Wiley Modification of red cell membrane structure by cholesterol rich lipid dispersions J. Clin. Invest. 55 1975 115 126
39. E. Ernst, and W. Koenig Fibrinogen and cardiovascular risk Vasc. Med. 2 1997 115 125
40. P. Maison, L. Mennen, and D. Sapinho A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration Atherosclerosis 160 1 2002 155 160
41. K. Kon Koh, J. Yeal Ahn, and S. Hwan Han Effects of fenofibrate on lipoproteins, vasomotor function and serological markers of inflammation, plaque stabilization and hemostasis Atherosclerosis 174 2 2004 379 383
42. V.K. Tsimihodimos, A. Kostoula, and A. Kakafika Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values J. Cardiovasc. Pharmacol. Ther. 9 1 2004 27 33